 |
|
|
| |
International Workshop on HIV & Hepatitis Virus Drug Resistance
5-9 June 2012, Sitges, Spain
|
| |
| |
- Report from International Workshop on HIV & Hepatitis Virus Drug Resistance 2nd Report, June 5-9 2012 Sitges, Spain - Written for NATAP by Mark A. Wainberg, PhD, McGill University AIDS Centre, Jewish General Hospital, Montreal, Canada
(06/20/12)
- 1st Report - Report from International Workshop on HIV & Hepatitis Virus Drug Resistance 5-9 June 2012, Sitges, Spain -
Written for NATAP by Mark A. Wainberg, PhD, McGill University AIDS Centre, Jewish General Hospital, Montreal, Canada
(06/18/12)
- Deep sequencing analysis of rilpivirine virologic failures in the Phase III studies ECHO and THRIVE shows no association with the presence of minority resistance associated variants at baseline (part II) (06/26/12)
- Deep sequencing analysis of rilpivirine virologic failures in the Phase III studies ECHO and THRIVE shows no association with the presence of minority resistance-associated variants at baseline (06/26/12)
- Jak inhibitors exhibit a novel mechanism of HIV inhibition in primary human and rhesus macaque macrophages and lymphocytes: 'functional cure?' (06/20/12)
- Reverse transcriptase connection-domain mutations were not associated with virologic failure or phenotypic resistance in rilpivirine-treated patients from the ECHO and THRIVE Phase III trials (Week 96 analysis) (06/18/12)
- Comparison of the Antivirogram and PhenoSense assays to determine phenotypic susceptibility to rilpivirine in patient samples from the Phase III ECHO and THRIVE trials (06/18/12)
- Integrated Analysis of Emergent Drug Resistance from the HIV-1 Phase 3 QUAD Studies through Week 48 (06/18/12)
- Effect of Primary Elvitegravir Resistance Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness (06/18/12)
- Genotypic and phenotypic correlates of virologic response to the attachment inhibitor BMS-626529 in a short-term monotherapy study with its prodrug BMS-663068 (06/15/12)
- The in vitro cross-resistance profile of the NRTI BMS-986001 against known NRTI resistance mutations (06/15/12)
- Resistance and Potency of GS-7340, a Next-Generation Tenofovir Prodrug (06/15/12)
- Switching the NNRTI or the PI/r to Maraviroc in Aviremic Subjects Infected with RS HIV by V3 Loop Population Sequencing: 48 week, Prospective, Controlled, Pilot Study (06/15/12)
- Combinations of Primary and Secondary Integrase Mutations in the VIKING Pilot Study: Effects on and Rationale for Dolutegravir Dissociation (06/15/12)
-
Dolutegravir Treatment of HIV Subjects With Raltegravir Resistance: Integrase Resistance Evolution in Cohort II of the VIKING Study (06/15/12)
- High Barrier to Resistance for Dolutegravir (DTG, S/GSK1349572) Against Raltegravir-Resistant Y143 Mutants: An In Vitro Passage Study (06/15/12)
|
|
| |
|
|
|
|
|
|
